{"organizations": [], "uuid": "15090c1770c087c222cf8b01dc1458be08641e12", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "//sc.cnbcfm.com/applications/cnbc.com/staticcontent/img/cnbc_logo.gif", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/04/business-wire-biogen-to-report-fourth-quarter-and-year-end-2017-financial-results-on-january-25-2018-updated-call-timing.html", "country": "US", "domain_rank": 767, "title": "Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018- Updated Call Timing", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T00:01:00.000+02:00", "replies_count": 0, "uuid": "15090c1770c087c222cf8b01dc1458be08641e12"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/04/business-wire-biogen-to-report-fourth-quarter-and-year-end-2017-financial-results-on-january-25-2018-updated-call-timing.html", "ord_in_thread": 0, "title": "Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018- Updated Call Timing", "locations": [], "entities": {"persons": [], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "cambridge", "sentiment": "none"}], "organizations": [{"name": "biogen inc.", "sentiment": "negative"}, {"name": "biogen", "sentiment": "negative"}, {"name": "biib", "sentiment": "negative"}, {"name": "company", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and year-end 2017 financial results on Thursday, January 25, 2018, before the financial markets open.\nFollowing the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:00 am ET. To access the live webcast, please go to the investor relations section of Biogen’s website at www.biogen.com/investors . Following the live webcast, an archived version of the call will be available at the same URL.\nAbout Biogen\nThrough cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com . Follow us on social media – Twitter , LinkedIn , Facebook , YouTube .\n //www.businesswire.com/news/home/20180104006059/en/\nBiogen\nKaren Jewell, 781.464.2442\nInvestor Relations\nSource: Biogen", "external_links": ["http://www.businesswire.com/news/home/20180104006059/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.biogen.com&esheet=51738030&newsitemid=20180104006059&lan=en-US&anchor=Biogen+Inc.&index=1&md5=9e4b1b0473b627d0b4d1d48486d18b16", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.biogen.com&esheet=51738030&newsitemid=20180104006059&lan=en-US&anchor=www.biogen.com&index=3&md5=261201497114c05e49d68d1855381c9c", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2Fbiogen&esheet=51738030&newsitemid=20180104006059&lan=en-US&anchor=Twitter&index=4&md5=1c6539b136596c4b8cae2a4dbafe1942", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbiogen-&esheet=51738030&newsitemid=20180104006059&lan=en-US&anchor=LinkedIn&index=5&md5=b6233e681cd5798ae5f71ca7267d05fd", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.biogen.com%2Fen_us%2Finvestors.html&esheet=51738030&newsitemid=20180104006059&lan=en-US&anchor=www.biogen.com%2Finvestors&index=2&md5=68d2df83ad7483bd6d540603e636ef7e", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.youtube.com%2Fc%2Fbiogen&esheet=51738030&newsitemid=20180104006059&lan=en-US&anchor=YouTube&index=7&md5=13dc26dc46edabc708bcc0c9198eb551", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.facebook.com%2FBiogenScienceEd%2F&esheet=51738030&newsitemid=20180104006059&lan=en-US&anchor=Facebook&index=6&md5=923faebf581aa4e4b53514627de18704"], "published": "2018-01-05T00:01:00.000+02:00", "crawled": "2018-01-05T01:18:44.000+02:00", "highlightTitle": ""}